Daniel Shur
@teleodaniel • 1,472 subscribers
Spreading ideas to enable radical life extension and a sci-fi future @FreeRadicalsBio. Strategy principal @ Google, prev. McKinsey and Neuro / Physics @ Penn
Videos
Twenty years ago, Derya Unutmaz, MD predicted we would reverse aging by 2045. People thought he was crazy. Now, he thinks he was too conservative, and has moved the date up to 2040 because AGI arrived earlier than he expected. I sat down with Derya to ask if such bold predictions are too fatalistic. Is the future guaranteed? Shall we just sit back and wait for AI to save us? Derya disagreed. The golden age for humanity is within our sights, but there is much work to be done. Academia is failing us. If it doesn’t adapt to the pace of progress AI enables, we have no shot at curing aging this century. And we need to invest trillions into collecting the data that superintelligence will need to solve biology. If we pull it off, the future can be brighter than anyone imagines. Watch the full episode below, or look up Free Radicals (Free Radicals) on your favorite podcasting platform. Special thank you to Adam Gries and for hosting us at Vitalist Bay (May 14-17)! Intro AGI arrived early, accelerating the timeline to biosingularity Are we really in the takeoff now? Superintelligence can help us build a world model of biology Aging as the breakdown of biological resilience The case for investing trillions into biological data The economic return on curing aging AI is accelerating science but academics are stuck in the past How AI can liberate humanity from biological constraints Derya’s Human 2.0 dream Testing the latest OpenAI models and rethinking the PhD Agency, jobs, and free will in an AI world Science fiction & Derya’s case for a coming golden age
Daniel Shur54,594 просмотров • 11 дней назад
Two young Harvard professors are coming for the supplements industry. Omar Abudayyeh and Jonathan Gootenberg run a joint lab at Harvard Medical School, have co-founded 4 biotechs, and raised over $300M to develop genetic medicines and diagnostics. But what surprised me most: they think like consumer tech founders, not academics. They start with what people actually want and work backwards from there. And best of all? They’re totally longevity-pilled. Consumers want to feel younger and healthier, and big pharma is waking up to it. In this week’s episode of the Free Radicals podcast, we discuss the biology of aging, the future of longevity therapeutics, and how Harvard can bring legitimacy to the supplements industry. One of my favorite episodes yet. Be sure to follow me, Eric Dai and Free Radicals to stay up to date on the latest news in longevity biotech!
Daniel Shur22,624 просмотров • 4 месяцев назад
Today I am launching the Free Radicals podcast with Eric Dai . Every Tuesday, we’ll be releasing long form conversations with the visionaries giving humanity control over biology and working to dramatically extend human lifespan. We’re thrilled to host Celine Halioua, Founder + CEO Loyal, for our inaugural episode. Celine is building the world’s first lifespan extension drugs for dogs. Follow me, Eric Dai and Free Radicals for new episodes every Tuesday. 00:00:00 - Intro 00:01:51 - Celine’s background 00:05:00 - Dropping out of academia 00:07:50 - Finding ways to increase free will 00:09:36 - How to align financial incentives with longevity 00:14:52 - Longevity drugs should be boring 00:21:24 - Celine’s leadership style 00:24:08 - Advice on fundraising and constructing feedback loops 00:26:52 - Loyal’s fundraising history 00:27:57 - Building for Zero Billion Dollar Markets 00:29:11 - How to succeed in biotech 00:30:21 - How to find blockbuster opportunities 00:33:25 - How to create a gold rush in longevity 00:35:25 - The problem with the aging field 00:39:32 - How to identify signal from noise 00:41:54 - AI applications to biology 00:45:15 - Importance of naiveté 00:47:24 - FREE RADICALS
Daniel Shur29,517 просмотров • 9 месяцев назад
Today’s guest on the Free Radicals podcast is Michael Ringel, JD PhD, COO Life Biosciences and former Managing Director at Boston Consulting Group. Michael is a leader in longevity and pharma who spent 25+ years advising top pharma companies on their R&D strategy. He is now COO at Life Biosciences where he is bringing the first ever partial epigenetic reprogramming therapy to human clinical trials - a major milestone for the longevity industry. In this episode, we discuss Michael’s insightful paper on why aging is an optimization by evolution, why that means it’s malleable, and how to push the longevity field forward. Michael also sits on the US board of Hevolution Foundation and on the board of the AFAR. Be sure to follow me and Eric Dai to stay up to date on the latest news in longevity biotech! 0:00 Intro 2:30 Why aging is an optimization by evolution 15:10 Why scientists miss the role of evolution in aging 19:31 Evidence that aging is a regulated process 24:40 Hormesis and adaptive stress responses 28:55 The promise of partial epigenetic reprogramming in humans 35:08 Life Bio's first therapy proceeding to clinical trials 47:47 Why targeting the eye, particularly glaucoma and NION, is a strategic choice 52:03 The pharma industry's perspective on anti-aging research 56:39 The importance of public engagement for funding and policy change 1:05:42 Reasons for optimism in longevity 1:08:26 Advice on how to have an impactful and interdisciplinary career 1:11:54 The ethical case for longevity 1:17:34 Concrete steps for audience members to support longevity research
Daniel Shur16,988 просмотров • 5 месяцев назад
Today’s guest on the Free Radicals podcast is José Luis Ricón Fernández de la Puente, head of theory Retro Biosciences and blogger Jose is a prolific blogger, covering a wide breadth of topics across economics, philosophy, progress studies, science funding, much more, and of course longevity. His works have been published by a16z, Works in Progress and Adam Smith Institute. Our conversation is wide ranging, spanning a deep dive on Retro’s work to replace and engineer microglia to rejuvenate the brain and how our cells have the ability to turn back the aging clock but choose not to. We also covered the technological stagnation and why biological engineering is the new frontier of progress, as well as philosophical topics like transhumanism and how a future of total biological control might impact our values and way of life. Be sure to follow me and Eric Dai to stay up to date on the latest news in longevity biotech! And Special thank you to NFX & omri_drory for lending us their beautiful podcasting studio! 0:00 Intro 2:49 What is aging & why cells have a tough choice to make 9:02 When cells choose to reverse aging themselves 12:43 Cellular vs Organismal Aging & the magic wand experiment 18:31 What is reprogramming 22:40 How reprogramming plays a role in DNA damage repair 25:42 Do we already know how to cure aging? FOXO3! 28:37 How to cut through the complexity of interconnected biology 32:32 Why transcription factors are so great for intervening 36:49 Does a rejuvenation program exist already in the genome 38:51 Michael Levin: from thinking in terms of genes to morphogenesis 48:14 Tech stagnation and why physics is cooked 55:03 Why doesn't the world look more futuristic 57:26 Transhumanism & asking ourselves what we want out of life 1:05:34 Do we need war for technological progress 1:09:31 Government role in science funding 1:15:06 How Jose became the Head of Theory at Retro 1:24:53 How AI might put software engineers out of a job, and push them towards biotech 1:27:28 What it takes to get a flywheel in biotech 1:29:04 Rejuvenation vs Prevention 1:34:23 Aging is the coolest hardest problem to work on 1:36:09 What does it take to cure aging 1:42:25 Delivery mechanisms for genetic therapies 1:48:53 Retro's work to replace microglia and engineer them outside the body 1:59:10 Consciousness 2:00:39 Jose's Origin Story
Daniel Shur13,644 просмотров • 5 месяцев назад
Больше нет контента для загрузки